Drug Profile


Alternative Names: HAL-MEP1; Peanut allergy immunotherapy - HAL Allergy; Peanut allergy vaccine - HAL Allergy; Peanut extract - HAL Allergy

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator HAL Allergy
  • Class Allergens; Antiallergics; Food allergy immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Peanut hypersensitivity

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Peanut-hypersensitivity in Denmark (SC)
  • 03 Mar 2017 Safety data from a phase I trial in Peanut hypersensitivity presented at the 2017 Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI-2017)
  • 01 Dec 2016 Phase-I clinical trials in Peanut hypersensitivity (In children, In adolescents, In adults) in USA (SC) (NCT02991885)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top